Celcuity Inc. (CELC)

Market Cap	222.32M
Revenue (ttm)	n/a
Net Income (ttm)	-40.37M
Shares Out	21.69M
EPS (ttm)	-2.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	303,443
Open	10.31
Previous Close	10.36
Day's Range	10.16 - 10.86
52-Week Range	4.81 - 14.40
Beta	0.63
Analysts	Buy
Price Target	25.16 (+145.46%)
Earnings Date	May 15, 2023

About CELC

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with horm...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 20, 2017
• Employees: 39
• Stock Exchange: NASDAQ
• Ticker Symbol: CELC

Analyst Forecast

According to 10 analysts, the average rating for CELC stock is "Buy." The 12-month stock price forecast is $25.16, which is an increase of 145.46% from the latest price.

Price Target

$25.16

(145.46% upside)

Analyst Consensus: Buy